Nothing Special   »   [go: up one dir, main page]

WO2013165972A3 - Anti-hepatitis b virus antibodies and use thereof - Google Patents

Anti-hepatitis b virus antibodies and use thereof Download PDF

Info

Publication number
WO2013165972A3
WO2013165972A3 PCT/US2013/038802 US2013038802W WO2013165972A3 WO 2013165972 A3 WO2013165972 A3 WO 2013165972A3 US 2013038802 W US2013038802 W US 2013038802W WO 2013165972 A3 WO2013165972 A3 WO 2013165972A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
sample
virus
detecting
binding agent
Prior art date
Application number
PCT/US2013/038802
Other languages
French (fr)
Other versions
WO2013165972A2 (en
Inventor
Shuji Sato
Sean Andre BEAUSOLEIL
Wan Cheung CHEUNG
Roberto D. POLAKIEWICZ
Original Assignee
Cell Signaling Technology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology, Inc. filed Critical Cell Signaling Technology, Inc.
Publication of WO2013165972A2 publication Critical patent/WO2013165972A2/en
Publication of WO2013165972A3 publication Critical patent/WO2013165972A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This disclosure provides anti-hepatitis B virus antibodies and methods of treatment, prophylaxis, detection, and diagnosis using the same. In an aspect, the disclosure features methods of detecting a hepatitis B virus or hepatitis B surface antigen in a sample that include contacting a sample with a binding agent (e.g., antibody) disclosed herein; and detecting binding of the binding agent to the sample, thereby detecting a hepatitis B virus or hepatitis B surface antigen in the sample. In yet another aspect, the disclosure features methods of inhibiting hepatitis B virus infection of a cell (e.g., a hepatocyte) that include contacting the cell with a binding agent (e.g., antibody disclosed herein.
PCT/US2013/038802 2012-04-30 2013-04-30 Anti-hepatitis b virus antibodies and use thereof WO2013165972A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261640361P 2012-04-30 2012-04-30
US61/640,361 2012-04-30
US201361787143P 2013-03-15 2013-03-15
US61/787,143 2013-03-15

Publications (2)

Publication Number Publication Date
WO2013165972A2 WO2013165972A2 (en) 2013-11-07
WO2013165972A3 true WO2013165972A3 (en) 2014-02-27

Family

ID=49515018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/038802 WO2013165972A2 (en) 2012-04-30 2013-04-30 Anti-hepatitis b virus antibodies and use thereof

Country Status (1)

Country Link
WO (1) WO2013165972A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094644B1 (en) * 2014-01-16 2019-07-24 Mondelli, Mario Umberto Franceso Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP3324996A4 (en) * 2015-07-22 2019-04-17 Scholar Rock, Inc. Gdf11 binding proteins and uses thereof
ES2881642T3 (en) 2015-09-15 2021-11-30 Scholar Rock Inc Anti-pro-myostatin / latent myostatin antibodies and uses thereof
MX2018008369A (en) 2016-01-08 2019-05-15 Scholar Rock Inc Anti-pro/latent myostatin antibodies and methods of use thereof.
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
ES2830440T3 (en) 2016-06-13 2021-06-03 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
WO2018039514A1 (en) * 2016-08-25 2018-03-01 Vanderbilt University Antibody-mediated neutralization of ebolaviruses
HRP20230308T1 (en) 2017-01-06 2023-05-12 Scholar Rock, Inc. Treating metabolic diseases by inhibiting myostatin activation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011495A1 (en) * 1992-11-06 1994-05-26 Sandoz, Ltd. Production of human monoclonal antibodies active against hepatitis b surface antigen
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20080152658A1 (en) * 2005-04-18 2008-06-26 Shlomo Dagan Stabilized Anti-Hepatitis B (Hbv) Antibody Formulations
WO2012017003A1 (en) * 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011495A1 (en) * 1992-11-06 1994-05-26 Sandoz, Ltd. Production of human monoclonal antibodies active against hepatitis b surface antigen
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20080152658A1 (en) * 2005-04-18 2008-06-26 Shlomo Dagan Stabilized Anti-Hepatitis B (Hbv) Antibody Formulations
WO2012017003A1 (en) * 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein

Also Published As

Publication number Publication date
WO2013165972A2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
WO2013165972A3 (en) Anti-hepatitis b virus antibodies and use thereof
WO2014015194A3 (en) Methods for detecting and measuring aggregation
MX2020009021A (en) Assays for detecting the presence or amount of an anti-drug antibody.
WO2013070776A8 (en) Neutralizing gp41 antibodies and their use
AU2018200278B2 (en) Antibodies to aripiprazole and use thereof
WO2012100235A3 (en) Systems and methods for sample use maximization
WO2014028378A3 (en) Methods and systems for detecting biological components
MX2019001767A (en) Hcv core lipid binding domain monoclonal antibodies.
EP3933406A3 (en) Antibodies to risperidone and use thereof
WO2014165082A3 (en) Antibodies and methods of detection
BR112012016119A2 (en) live biological charge detection using microparticles
MX362075B (en) Hcv antigen-antibody combination assay and methods and compositions for use therein.
WO2012054589A3 (en) Conduit-containing devices and methods for analyte processing and detection
WO2014031668A3 (en) Antibodies to quetiapine and use thereof
PL2821415T3 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
WO2012129164A3 (en) Biosensor
WO2014031662A3 (en) Antibodies to olanzapine and use thereof
MX336109B (en) Immuno-pet imaging of antibodies and immunoconjugates and uses therefor.
MX2016005686A (en) Competitive ligand binding assay for detecting neutralizing antibodies.
IT201600073964A1 (en) NANO SWITCH BASED ON NUCLEOTIDES AND METHODS FOR DETECTING ANTIBODIES AND OTHER ANALYTES
MX2015004419A (en) Detecting an analyte and determining the concentration of an analyte using magnetizable beads.
TWI800483B (en) Anti-human hemoglobin monoclonal antibody or antibody set, anti-human hemoglobin monoclonal antibody immobilized insoluble carrier particle, and measurement reagent or measurement method using the same
EP3004375A4 (en) Protease-responsive peptide biosensors and methods for analyte detection
WO2012032512A3 (en) Methods and kits for the detection of an infection in subjects with low specific antibody levels
EP2239575A4 (en) Reagent for detecting hiv-1 antigen and detection method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13784796

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13784796

Country of ref document: EP

Kind code of ref document: A2